About
About LB6V
LB6V (development code PF-07307405, formerly VLA15) is an investigational vaccine designed to protect against Lyme disease. It is being co-developed by Pfizer and Valneva.
Type
Multivalent recombinant protein vaccine
Target
Outer Surface Protein A (OspA)
Serotypes
6 most common Borrelia serotypes in N. America & Europe
Ages
5 years and older
Schedule
Primary series of 3 doses + 1 booster
Developers
Pfizer Inc. and Valneva SE
Why a 6-valent design?
Different Borrelia species and strains express different versions of OspA. By including six OspA serotypes, LB6V is designed to cover the predominant strains responsible for Lyme disease across the United States, Canada, and Europe — broader coverage than any previously approved Lyme vaccine.
Partnership
Valneva originated the program and partnered with Pfizer in 2020 to advance late-stage clinical development, manufacturing scale-up, and worldwide commercialization.